Skip to main content

Advertisement

SpringerLink
Log in

Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Neither accurate incidence nor survival data for pediatric patients with hematological malignancies (HM) have been available in Japan to date. Incidence of patients under 20 years of age, who were diagnosed with HM from 2006 to 2010, and their two-year survival rate (2y-OS) were obtained from disease registry data maintained by the Japan Society of Pediatric Hematology (JSPH). A total of 5,287 cases of HM were identified during this period. Acute lymphoblastic leukemia (ALL, 46.6 %) showed the highest incidence, followed by acute myeloid leukemia (AML, 16.7 %), non-Hodgkin lymphoma (NHL, 11.9 %), and histiocytosis (11.8 %). ALL, AML and histiocytosis were common in younger patients aged 1–4, while NHL tended to occur more frequently in older patients aged 5–14. The 2y-OS of HM was 91.6 %, with that for the most common B-precursor ALL rising to 96.2 %. The 2y-OS for M3 AML, lymphoblastic-B-precursor or diffuse large B cell NHL, Hodgkin lymphoma, myeloproliferative disorders, and Langerhans cell histiocytosis was >95 %. There were no gender differences in prognosis, while infants (88.0 %) and adolescents aged 15–19 (90.6 %) tended toward a poorer prognosis. This is the first report to describe incidence and survival times from the nationwide JSPH disease registry. More precise data with longer follow-up is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. The Research Program for the Treatment of Chronic Pediatric Diseases of Specified Categories: Department of Health Policy. Available from URL: http://www.nch.go.jp/policy/shoumann.htm. Accessed October, 2012.

  2. Research group of the Treatment of Chronic Pediatric Diseases of Specified Categories. Available from URL: http://www.aiiku.or.jp/aiiku/mch/syoman/syo.html. Accessed October, 2012.

  3. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42(2):139–47.

    Article  PubMed  Google Scholar 

  4. Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: a trend or a chance? J Pediatr. 1997;130(4):557–60.

    Article  PubMed  CAS  Google Scholar 

  5. The Committee of the Japan Children’s Cancer Registry. The Japan Children’s Cancer Registry: outline, results, and perspectives. In: Watanabe S, Tominaga S, Kakizoe T, editors. Cancer Treatment and survival. Tokyo: CRC Press; 1995.

    Google Scholar 

  6. Ajiki W, Hanai A, Tsukuma H, Hiyama T, Fujimoto I. Incidence of childhood cancer in Osaka, Japan, 1971–1988: reclassification of registered cases by Birch’s scheme using information on clinical diagnosis, histology and primary site. Jpn J Cancer Res. 1994;85(2):139–46.

    Article  PubMed  CAS  Google Scholar 

  7. Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):255–64.

    Article  PubMed  CAS  Google Scholar 

  8. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663–9.

    Article  PubMed  Google Scholar 

  9. Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. Leukemia. 2010;24(2):406–18.

    Article  PubMed  CAS  Google Scholar 

  10. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL–BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–84.

    Article  PubMed  CAS  Google Scholar 

  11. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):345–54.

    Article  PubMed  CAS  Google Scholar 

  12. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol. 2009;10(10):957–66.

    Article  PubMed  CAS  Google Scholar 

  13. Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009;21(1):1–8.

    Article  PubMed  Google Scholar 

  14. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–74.

    Article  PubMed  CAS  Google Scholar 

  15. Disease Registry Committee for the Japanese Society of Pediatric Hematology. Annual Report of Nationwide Survey 2008. Jpn J Pediatr Hematol. 2009;23:213–9.

    Google Scholar 

  16. Disease Registry Committee for the Japanese Society of Pediatric Hematology. Annual Report of Nationwide Survey 2009. Jpn J Pediatr Hematol. 2010;24:182–9.

    Google Scholar 

  17. Disease Registry Committee for the Japanese Society of Pediatric Hematology, Diagnostic guidelines for hematological diseases. Jpn J Pediatr Hematol. 2009;21 Suppl 5/6:1–76.

    Google Scholar 

  18. Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev. 2003;29(1):31–44.

    Article  PubMed  Google Scholar 

  19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  20. Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36.

    Article  PubMed  CAS  Google Scholar 

  21. Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol. 2012;159(3):259–76.

    Article  PubMed  Google Scholar 

  22. Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol. 1993;11(6):1046–54.

    PubMed  CAS  Google Scholar 

  23. Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001;98(6):1714–20.

    Article  PubMed  CAS  Google Scholar 

  24. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56–62.

    Article  PubMed  CAS  Google Scholar 

  25. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007–13.

    Article  PubMed  CAS  Google Scholar 

  26. Imaizumi M, Tawa A, Hanada R, Tsuchida M, Tabuchi K, Kigasawa H, et al. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol. 2011;152(1):89–98.

    Article  PubMed  CAS  Google Scholar 

  27. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2007;25(34):5442–7.

    Article  PubMed  CAS  Google Scholar 

  28. Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003–06 from the Japan Association of Childhood Leukaemia Study. Br J Haematol. 2012;159(2):204–10.

    Article  PubMed  Google Scholar 

  29. Koga Y, Kumagai M, Takimoto T, Mimaya J, Nakazawa A, Horibe K, et al. Retrospective analysis of 157 patients with pediatric Hodgkin lymphoma in Japan: investigation by four pediatric cancer study groups. Rinsho Ketsueki. 2012;53(4):443–9.

    PubMed  Google Scholar 

  30. Manipadam MT, Nair S, Viswabandya A, Mathew L, Srivastava A, Chandy M. Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India. World J Pediatr. 2011;7(4):318–25.

    Article  PubMed  Google Scholar 

  31. Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children’s Cancer Study Group. J Clin Pathol. 1997;50(2):128–34.

    Article  PubMed  CAS  Google Scholar 

  32. Spitz MR, Sider JG, Johnson CC, Butler JJ, Pollack ES, Newell GR. Ethnic patterns of Hodgkin’s disease incidence among children and adolescents in the United States, 1973–82. J Natl Cancer Inst. 1986;76(2):235–9.

    PubMed  CAS  Google Scholar 

  33. Percy CL, Smith MA, Linet M, Gloeckler Ries LA, Friedman DL. Lymphoma and reticuloendothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG, et.al., eds. Cancer incidence and survival among children and adolescents. United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program, 1999;35–49. Available at: http://www.acco.org/LinkClick.aspx?fileticket=CGsKkvHaH1Y%3D&tabid=670. Accessed November, 2012.

  34. Fujita N, Kobayashi R, Takimoto T, Nakagawa A, Ueda K, Horibe K. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma. 2011;52(2):223–9.

    Article  PubMed  CAS  Google Scholar 

  35. Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, et al. Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children’s Cancer Study Group NHL B9604 protocol. Leuk Lymphoma. 2008;49(4):757–62.

    Article  PubMed  CAS  Google Scholar 

  36. Tsurusawa M, Katano N, Hirota T, Ito M, Yanase T, Asami K, et al. Studies of childhood non-Hodgkin’s lymphoma-treatment results with the CCLSG NHL 960 protocol. Children’s Cancer and Leukemia Study Group (CCLSG). Rinsho Ketsueki. 1998;39(11):1092–8.

    PubMed  CAS  Google Scholar 

  37. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–306.

    PubMed  CAS  Google Scholar 

  38. Bhatia S, Nesbit ME Jr, Egeler RM, Buckley JD, Mertens A, Robison LL. Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr. 1997;130(5):774–84.

    Article  PubMed  CAS  Google Scholar 

  39. Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107(3):613–9.

    Article  PubMed  Google Scholar 

  40. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58–65.

    Article  PubMed  Google Scholar 

  41. Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84.

    Article  PubMed  CAS  Google Scholar 

  42. Kikuchi A, Hasegawa D, Ohtsuka Y, Hamamoto K, Kojima S, Okamura J, et al. Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study. Br J Haematol. 2012;158(5):657–61.

    Article  PubMed  Google Scholar 

  43. Hasegawa D, Manabe A, Yagasaki H, Ohtsuka Y, Inoue M, Kikuchi A, et al. Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99). Pediatr Blood Cancer. 2009;53(6):1011–5.

    Article  PubMed  Google Scholar 

  44. Yoshida N, Hirabayashi S, Watanabe S, Zaike Y, Tsuchida M, Yoshimi A, et al. Prognosis of 75 patients with juvenile myelomonocytic leukemia: prospective study by MDS committee in the Japanese Society of Pediatric Hematology. Rinsho Ketsueki. 2011;52(12):1853–8.

    PubMed  Google Scholar 

Download references

Acknowledgments

The survey on hematological malignancies incidence in Japan was conducted with contributions from the 187 institutions, described in Appendix 1. The authors thank deeply the members, especially Kaori Nagai, Kazumi Takeuchi, Maki Nishimura, and Midori Otomo of the Data Management Department of the NPO-OSCR, for their support in the management of the electronic or paper-based survey system and in the cleaning and tabulation of the registered data.

Conflict of interest

The authors have no financial relationship to declare.

Author information

Authors and Affiliations

  1. Clinical Research Center, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan

    Keizo Horibe & Akiko M. Saito

  2. Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan

    Tetsuya Takimoto

  3. Ibaraki Children’s Hospital, Ibaraki, Japan

    Masahiro Tsuchida

  4. Department of Pediatrics, St. Luke’s International Hospital, Tokyo, Japan

    Atsushi Manabe

  5. Department of Pediatrics, Nara Medical University, Nara, Japan

    Midori Shima

  6. Toho University Omori Medical Center, Tokyo, Japan

    Akira Ohara

  7. Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan

    Shuki Mizutani

Authors
  1. Keizo Horibe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akiko M. Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiro Tsuchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsushi Manabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Midori Shima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akira Ohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuki Mizutani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keizo Horibe.

Appendix

Appendix

See appendix Table 4.

Table 4 Institutions with registered cases of hematological malignancies
Full size table

About this article

Cite this article

Horibe, K., Saito, A.M., Takimoto, T. et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 98, 74–88 (2013). https://doi.org/10.1007/s12185-013-1364-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1364-2

Keywords

Search

Navigation